Home2018-10-03T10:10:25+00:00
Inspecting Biotech Catalysts

An unbiased & independent look at the scientific and regulatory issues surrounding healthcare, pharma, and biotech catalysts.

Disclaimer; click here.

All Articles
TickerActionArticleDrugCompany
ATRS9/29/18 - ApprovedXyosted vs. the AlternativesXyostedAntares Pharma
PGNX7/30/18 - ApprovedCorrecting a Common Legal & Regulatory MisconceptionAzedraProgenics Pharmaceuticals
INSY7/28/18 - CRLThe AdCom vs. the FDABuvayaInsys Therapeutics
KTOV5/31/18 - ApprovedThe Legal Cloud Hanging Over the Science (ARCHIVED)ConsensiKitov Pharmaceuticals
TXMD5/29/18 - ApprovedDoes TXMD Have Anything to Really Worry About? (ARCHIVED)ImvexxyTherapeuticsMD
RIGL4/17/18 - ApprovedRigel's Fight for Fostamatinib’s FDA Approval (ARCHIVED)TavalisseRigel Pharmaceuticals
THERF3/6/18 - ApprovedIbalizumab Has a Reasonable Chance of Approval (ARCHIVED)TrogarzoTaiMed Biologics & Theratechnologies
SRNE2/28/18 - ApprovedThe Scientific Issues Surrounding ZTlido's NDA (ARCHIVED)ZTlidoSorrento Therapeutics & Scilex Pharmaceuticals
KMPH2/23/18 - Approved w/o AD label.Apadaz: The Best Case Scenario (ARCHIVED)ApadazKemPharm
APRI2/16/18 - CRLWill the FDA Approve Vitaros?VitarosApricus Biosciences
zzz-2/15/17-Can You Trust a Company's CRL PR?zzz-zzz-
zzz-2/15/17-A Common Trick Healthcare Companies Use to Sway Our Judgementzzz-zzz-